All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in all‐cause mortality D60 or more compared with standard care/placebo (low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in adverse events ( compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes clinical improvement D60 or moree compared with standard care/placebo (very low certainty).
1 finding from 1 review
Migraine frequency Number of attacks · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Duration of attacks per day (minutes) · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Severity of Raynaud's attack · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Patient global · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
side‐effects ‐ side‐effects causing abandon · treatment of apnea
3 findings from 1 review
1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found